Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effect of avalglucosidase alfa on disease-specific and general patient-reported outcomes in treatment-naïve adults with late-onset Pompe disease compared with alglucosidase alfa: Meaningful change analyses from the Phase 3 COMET trial.
Toscano A, Pollissard L, Msihid J, van der Beek N, Kishnani PS, Dimachkie MM, Berger KI, DasMahapatra P, Thibault N, Hamed A, Zhou T, Haack KA, Schoser B. Toscano A, et al. Among authors: dimachkie mm. Mol Genet Metab. 2024 Feb;141(2):108121. doi: 10.1016/j.ymgme.2023.108121. Epub 2023 Dec 27. Mol Genet Metab. 2024. PMID: 38184428 Free article. Clinical Trial.
Applying the win ratio method in clinical trials of orphan drugs: an analysis of data from the COMET trial of avalglucosidase alfa in patients with late-onset Pompe disease.
Boentert M, Berger KI, Díaz-Manera J, Dimachkie MM, Hamed A, Riou França L, Thibault N, Shukla P, Ishak J, Caro JJ. Boentert M, et al. Among authors: dimachkie mm. Orphanet J Rare Dis. 2024 Jan 12;19(1):14. doi: 10.1186/s13023-023-02974-1. Orphanet J Rare Dis. 2024. PMID: 38216959 Free PMC article.
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative.
Oldroyd AGS, Callen JP, Chinoy H, Chung L, Fiorentino D, Gordon P, Machado PM, McHugh N, Selva-O'Callaghan A, Schmidt J, Tansley SL, Vleugels RA, Werth VP; International Myositis Assessment and Clinical Studies Group Cancer Screening Expert Group; Aggarwal R. Oldroyd AGS, et al. Nat Rev Rheumatol. 2024 May;20(5):315. doi: 10.1038/s41584-024-01111-x. Nat Rev Rheumatol. 2024. PMID: 38548933 No abstract available.
Correspondence on 'Current myositis clinical trials and tribulations' by Saygin et al.
Azevedo SF, Valenzuela A, Benitez CA, Isenberg DA, Naddaf E, Chinoy H, Vencovský J, Gupta L, McCann L, Kuwana M, Dimachkie MM, Shenoi S, Saketkoo LA, Machado PM. Azevedo SF, et al. Among authors: dimachkie mm. Ann Rheum Dis. 2024 Mar 28:ard-2024-225751. doi: 10.1136/ard-2024-225751. Online ahead of print. Ann Rheum Dis. 2024. PMID: 38548314 No abstract available.
Agreement between local and central anti-synthetase antibodies detection: results from the Classification Criteria of Anti-Synthetase Syndrome project biobank.
Loganathan A, Zanframundo G, Yoshida A, Faghihi-Kashani S, Bauer Ventura I, Dourado E, Bozan F, Sambataro G, Yamano Y, Bae SS, Lim D, Ceribelli A, Isailovic N, Selmi C, Fertig N, Bravi E, Kaneko Y, Saraiva AP, Jovani V, Bachiller-Corral J, Cifrian J, Mera-Varela A, Moghadam-Kia S, Wolff V, Campagne J, Meyer A, Giannini M, Triantafyllias K, Knitza J, Gupta L, Molad Y, Iannone F, Cavazzana I, Piga M, De Luca G, Tansley S, Bozzalla-Cassione E, Bonella F, Corte TJ, Doyle TJ, Fiorentino D, Gonzalez-Gay MA, Hudson M, Kuwana M, Lundberg IE, Mammen AL, McHugh NJ, Miller FW, Montecucco C, Oddis CV, Rojas-Serrano J, Schmidt J, Scirè CA, Selva-O'Callaghan A, Werth VP, Alpini C, Bozzini S, Cavagna L, Aggarwal R; CLASS Project. Loganathan A, et al. Clin Exp Rheumatol. 2024 Feb;42(2):277-287. doi: 10.55563/clinexprheumatol/s14zq8. Epub 2024 Mar 14. Clin Exp Rheumatol. 2024. PMID: 38488094 Free article.
Collaborative research in myositis-related disorders: MIHRA, a global shared community model.
Saketkoo LA, Paik JJ, Alexanderson H, Dimachkie MM, Ernste FC, Naddaf E, Shafranski B, Gupta L, Mecoli CA, Saygin D, Albayda J, Basharat P, Day JA, Valenzuela A, Bromley R, de Groot I, Edison SE, Lanis A, Lood C, Regardt M, Yi BY, Benitez AC, Chinoy H, Christopher-Stine L, Isenberg DA, Lang B, Oddis CV, van Royen A, Vencovsky J, Werth VP, Machado PM. Saketkoo LA, et al. Among authors: dimachkie mm. Clin Exp Rheumatol. 2024 Feb;42(2):207-212. doi: 10.55563/clinexprheumatol/hc1lsf. Epub 2024 Mar 4. Clin Exp Rheumatol. 2024. PMID: 38436382 Free article.
Phenotypic spectrum of inclusion body myositis.
Roy B, Dimachkie MM, Naddaf E. Roy B, et al. Among authors: dimachkie mm. Clin Exp Rheumatol. 2024 Feb;42(2):445-453. doi: 10.55563/clinexprheumatol/fhrx3q. Epub 2024 Feb 28. Clin Exp Rheumatol. 2024. PMID: 38436356 Free article. Review.
Performance of the 2017 EULAR/ACR Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review.
Saygin D, Glaubitz S, Zeng R, Bottai M, de Visser M, Dimachkie MM, Fiorentino D, Gerhardson I, Kuwana M, Miller FW, Needham M, Rider LG, Salem Y, Schlüter S, Shinjo SK, Wang G, Werth VP, Aggarwal R, Lundberg IE. Saygin D, et al. Among authors: dimachkie mm. Clin Exp Rheumatol. 2024 Feb;42(2):403-412. doi: 10.55563/clinexprheumatol/vuc5py. Epub 2024 Feb 28. Clin Exp Rheumatol. 2024. PMID: 38436279 Free article. Review.
171 results